Posts

Pfizer'

on
key drug from Pfizer's $43B Seagen acquisition failed a pivotal Phase 3 lung cancer trial; Pfizer's antibody-drug conjugate sigvotatug vedotin did not significantly improve overall survival versus docetaxel in previously treated non-squamous NSCLC; failure raises concerns about the near‑term value of Seagen assets and complicates Pfizer's oncology strategy. Sources: Pfizer's first new ADC from Seagen buy fails ph. 3 NSCLC trial Closely watched Pfizer lung cancer drug falls short in clinical trial Pfizer Deepens Bet on ADCs - ADC Summit 2026 Pfizer drug acquired in Seagen deal disappoints in lung cancer study 辉瑞肺癌疗法遇挫未伤根本 但其价值430亿美元的Seagen相关预期进一步降温 sigvotatug vedotin (PF-08046047) / Pfizer - LARVOL DELTA Pfizer ADC, from Seagen M&A, fails in phase III NSCLC trial | BioWorld Pfizer Terminates PF-08046032 Phase I Trial - AllSci Pfizer's Experimental Lung Cancer Drug Fails to Boost Survival [PDF] Generation Pipeline at ASCO 2026 - View PDF Pf...

Osanni Bio raises $190M to advance ophthalmology and cardiology pipeline, including dry AMD candidate

on

uniQure Announces Pricing of Upsized $225 Million Public Offering: Details and Highlights

on

Sangamo puts substantially all assets up for sale in bankruptcy, lines up Lilly and Astellas as buyers

on

Pfizer's first new ADC from Seagen acquisition fails Phase 3 NSCLC trial but may live on in earlier lines and combinations

on

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

on

Federal health agencies unveil plan to speed up Phase 1 clinical trials by 6 to 12 months

on

Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal

on

Merck Posts Encouraging Phase 3 Ulcerative Colitis Data But Roche Challenge Looms

on

Nura Bio Raises $73.8M Series B to Advance SARM1 Inhibitors for Neurodegeneration

on

Merck’s IBD Drug from $10.8B Prometheus Deal Claims First Phase 3 Win

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Villya Announces Breakthrough Data Demonstrating Enhanced Stability and Solubility for Insulin, GLP-1s

on